Status:
UNKNOWN
Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19
Lead Sponsor:
D'Or Institute for Research and Education
Collaborating Sponsors:
Brazilian Clinical Research Institute
Conditions:
Corona Virus Infection
COVID-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection.
Detailed Description
Several interactions by pre-existing therapies for chronic diseases, therapies used by SARS-CoV2 infection generate doubts about risks and benefits. Among these situations in which the current data in...
Eligibility Criteria
Inclusion
- Patients hospitalized with COVID-19 diagnosis using ACE inhibitors or blockers of angiotensin receptor;
- Patients ≥ 18 years old;
- Maximum use of 3 antihypertensive drugs;
- Sign the consent form.
Exclusion
- Severe evolution with orotracheal intubation, use of mechanical ventilation and / or hemodynamic instability in the first 24 hours until COVID-19 diagnosis confirmation;
- Patients hospitalized per decompensated congestive heart failure in the last 12 months;
- Use of Sacubitril/Valsartan
- Pregnancy
- Recent acute renal failure and shock
Key Trial Info
Start Date :
April 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT04364893
Start Date
April 9 2020
End Date
December 1 2020
Last Update
July 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Idor
São Paulo, Brazil